echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > The European Union approves the anti-epileptic drug Ontozry (cenobamate)

    The European Union approves the anti-epileptic drug Ontozry (cenobamate)

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Angelini pharmaceutical company, announced the European Commission (EC) has approved the use of anti- medsci.


    medsci.


    The approval is based on three key trials involving more than 1,900 patients.


    In addition, the 100% response rate for patients receiving Ontozry 100mg/day, 200mg/day, and 400mg/day were 4%, 11%, and 21%, respectively.


    Angelini Chief Medical Officer Agnese Cattaneo added: “It is very important for patients to choose new treatments because seizures can have a devastating impact on their lives.


     

    Original source:

    Original source:

    href="" target="_blank" rel="noopener">


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.